Giá trị tiên lượng của thang điểm MPRIEST trên bệnh nhân COVID-19 nhập viện tại thành phố Hồ Chí Minh
DOI: 10.38103/jcmhch.90.6
Abstract
ABSTRACT
PROGNOSTIC ACCURACY OF MPRIEST FOR ADVERSE OUTCOMES WITHIN 30 DAYS OF HOSPITALIZED COVID-19 PATIENTS IN HO CHI MINH CITY
Do Ngoc Quoc Duy1, Tran Ngoc Nguyen2, Tran Phuc An1, Dang Huy Hoang1, Tran Nien Ky1, Phan Hai Nam1, To Thi Ngan1, Ninh Hoang Phong1, Pham Thi Thao1, Vo Ngoc Trang1, Pham Ngoc Huy1, Van Trinh Ngoc Khanh1, Quy Khoa3, Nguyen Thi Xuan Dieu3, Nguyen Tuan Anh4
Objectives: The need for a simple yet effective tool to predict the severity of COVID-19 patients is essential. The mPRIEST score has been applied in some countries and contributed to solving the problem of health resource allocation. We aimed to investigate the prognostic accuracy of mPRIEST for adverse outcome of hospitalized COVID-19 patients in the Vietnamese population.
Methods: We conducted a retrospective observational cohort study of hospitalized COVID-19 patients at the Emergency Department in the University Medical Center Ho Chi Minh City during the period from April 2021 to January 2022. We collected data from the electronic medical record system, the information of variables at the time of admission to assess the mPRIREST score value. We used 30-day outcome data (death or receiving respiratory, cardiovascular or renal support) to determine the prognostic accuracy for adverse outcomes of the mPRIEST score.
Results: We analysed data of 339 adults, of whom 142 (41.9%) died or got organ support. Out of the 90 patients who died, 88 (97.8%) received at least one organ support. C-statistics (AUC) of the mPRIEST score for the overall outcome, death and organ support was 0.77 (95% CI 0.72 - 0.82); 0.72 (CI 95% 0.66 - 0.78); and 0.77 (95% CI 0.72 - 0.82), respectively. A cut - off > 9 points for a sensitivity of 65.5% and a specificity of 75.1%.
Conclusion: This data suggests that the mPRIEST score, which can be assessed from clinical variables alone, has potential for use in Emergency Department to predict mortality or organ support within 30 - day of hospitalized COVID-19 patients. This should be confirmed in more validation studies in diverse settings